May 22, 2026
Snore Wars: The Pill Awakens
Sleep research led to a new sleep apnea drug
A possible anti-snoring pill has people hopeful, skeptical, and very, very tired
TLDR: A decades-long sleep research project helped lead to a new sleep apnea drug that just posted encouraging late-stage trial results. Commenters are split between hopeful people desperate for alternatives to those sleep masks and skeptics saying the results sound modest and the hype may be too early.
A new sleep apnea drug is inching closer to reality, and the internet’s reaction is basically: finally — but also, prove it. The science story is real and serious: University of Toronto researcher Richard Horner spent decades studying why people stop breathing properly in their sleep, especially when the tongue and airway muscles go floppy at night. That work helped point drug makers toward a treatment now reporting positive phase 3 trial results. For the millions of people who snore, gasp, wake up exhausted, and don’t even know they have a condition, that’s huge news.
But the comments? That’s where the real late-night drama kicked off. One camp was deeply personal and painfully relatable, with people describing sleep apnea as life-wrecking, mood-crushing, and wildly underdiagnosed. One commenter basically turned the thread into a public service announcement, warning that constant fatigue and brain fog aren’t just “being bad at mornings.” Another shared a honeymoon horror story so brutal it sounded like a sitcom plot: he stayed awake so his wife could sleep because his snoring was that bad. Romance is alive, but barely breathing.
Then came the skeptics. Some readers called out the headline as premature, noting the drug — AD109 — is still in trials. Others zeroed in on the reported improvement, arguing that cutting only a few breathing interruptions per hour may not be enough for people with moderate or severe cases. And of course, this is the internet, so someone brought diet drugs into the brawl, arguing weight-loss medications may solve a huge chunk of cases anyway. In other words: hope, nitpicking, oversharing, and a side quest into obesity discourse — a perfect comment-section storm.
Key Points
- •University of Toronto professor Richard Horner’s research on sleep and breathing helped lead to a new sleep apnea treatment that recently showed positive phase 3 clinical trial results.
- •The article cites a 2024 study estimating that more than one in four Canadians have obstructive sleep apnea, while fewer than 10 per cent are formally diagnosed.
- •Obstructive sleep apnea involves repeated upper-airway collapse during sleep and is associated with risks including high blood pressure, heart disease, metabolic disorders and cognitive impairment.
- •Horner’s lab developed models to study natural sleep and identified noradrenaline in 2006 as important for activating the tongue muscle during wakefulness and some sleep stages.
- •In 2013, Horner’s team showed muscarinic receptors suppress tongue movement during REM sleep, helping define two pathways that contribute to sleep apnea.